

**Publication****Antimalarial chemoprophylaxis and the risk of neuropsychiatric disorders****JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)****ID** 2355884**Author(s)** Schneider, Cornelia; Adamcova, Miriam; Jick, Susan S; Schlagenhauf, Patricia; Miller, Mary K; Rhein, Hans-Georg; Meier, Christoph R**Author(s) at UniBasel** [Schneider, Cornelia](#) ; [Meier, Christoph R.](#) ;**Year** 2013**Title** Antimalarial chemoprophylaxis and the risk of neuropsychiatric disorders**Journal** Travel medicine and infectious disease**Volume** 11**Number** 2**Pages / Article-Number** 71-80

Case reports and epidemiological studies have associated the use of mefloquine with neuropsychiatric adverse events.; We used the General Practice Research Database to conduct a follow-up study with a nested case-control analysis. We assessed the risk of developing first-time anxiety, stress-related disorders/psychosis, depression, epilepsy or peripheral neuropathies in patients using mefloquine, chloroquine and/or proguanil, or atovaquone/proguanil for malaria chemoprophylaxis, as compared to unexposed travelers.; Compared to non-users of antimalarials, the adjusted odds ratio in the nested case-control analysis for users of mefloquine, chloroquine and/or proguanil, or atovaquone/proguanil were 0.71 (95% CI 0.56-0.90), 1.04 (95% CI 0.74-1.46), and 0.73 (95% CI 0.61-0.86) for anxiety or stress-related disorders combined, 0.54 (95% CI 0.41-0.71), 1.06 (95% CI 0.71-1.59), and 0.75 (95% CI 0.62-0.91) for depression, 0.69 (95% CI 0.35-1.36), 1.41 (95% CI 0.54-3.67), and 0.75 (95% CI 0.42-1.36) for epilepsy, and 1.22 (95% CI 0.50-2.99), 1.59 (95% CI 0.41-6.15), and 1.05 (95% CI 0.54-2.03) for neuropathies, respectively. The risk of all outcomes was higher in females than in males across all exposure categories.; The risk of neuropsychiatric disorders was similar for users and for non-users of anti-malarial chemoprophylaxis, with evidence for elevated risks in some subgroups.

**Publisher** Elsevier**ISSN/ISBN** 1477-8939**edoc-URL** <http://edoc.unibas.ch/41115/>**Full Text on edoc** No;**Digital Object Identifier DOI** 10.1016/j.tmaid.2013.02.008**PubMed ID** <http://www.ncbi.nlm.nih.gov/pubmed/23541791>**ISI-Number** WOS:000320413200001**Document type (ISI)** Journal Article